

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

VOLUNTARY ANNOUNCEMENT

**RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY
CHINESE MEDICINE**

This announcement is made by the board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development of the Company.

The Board is pleased to announce that the Company recently received the Certificate of Registration of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Chinese Medicine Council of Hong Kong (the “**Certificate**”), allowing “Dingzhi Wan 【Tong Ren Tang】” (“定志丸【同仁堂】”) to be sold in the Hong Kong Special Administrative Region of the People’s Republic of China (“**Hong Kong**”). The relevant details are as follows:

I. Basic Information of the Medicine

Name of the medicine: Dingzhi Wan 【Tong Ren Tang】 (定志丸【同仁堂】)

Registrant and address: Beijing Tong Ren Tang Chinese Medicine Company Limited at 3 Dai King Street, Tai Po Industrial Estate, New Territories, Hong Kong

Registration number: HKC-18863

Certificate validity period: Until 29 September 2031

II. Other Related Information of the Medicine

The functions and main indications of the “Dingzhi Wan 【Tong Ren Tang】” are to supplement qi and nourish the heart, and to calm and settle the mind. It is indicated for patterns of heart qi instability and deficiency of the five zang organs, manifested by worry, grief and unhappiness, restlessness of the heart spirit with a tendency to forgetfulness, symptoms mild in the morning and severe in the evening or recovered in the evening and relapse in the morning, and accompanied by severe vertigo during episodes. As at the date of this announcement, the Company has cumulatively invested approximately HK\$800,000 (unaudited) in the research and development of “Dingzhi Wan 【Tong Ren Tang】”. This product has not yet been launched for sale in the market.

III. Impact on the Company and Risk Warning

Upon obtaining the Certificate, “Dingzhi Wan 【Tong Ren Tang】” produced by the Company can be sold in Hong Kong, which is conducive to expanding the product lines of the Company and beneficial to the market expansion of the Company. The obtaining of the Certificate is not expected to have any material impact on the production, operation and performance of the Company for the time being. The sales of pharmaceutical products can be influenced by factors such as changes in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Yan Han
Chairman

Hong Kong, 8 October 2026

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Mr. Yan Han (*Chairman*)
Mr. Yue Zheng (*Vice Chairman*)
Mr. Wang Chi

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li